4-(2-二甲基氨基乙氧基)苯甲酸盐酸盐

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-二甲基氨基乙氧基)苯甲酸盐酸盐
• 英文名称: 4-(2-dimethylaminoethoxy)benzoic acid hydrochloride
• 英文别名: 4-(2-(dimethylamino)ethoxy)benzoic acid hydrogen chloride；4-(2-dimethylaminomethyl)benzoic acid hydrochloride；4-[2-(Dimethylamino)ethoxy]benzoic acid;hydron;chloride；4-[2-(dimethylamino)ethoxy]benzoic acid;hydron;chloride
• 化学式: C₁₁H₁₅NO₃*ClH
• 分子量: 245.706
• InChiKey: YVBNLWJELUWWQV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.75
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2-二甲基氨基乙氧基)苯甲酸盐酸盐 在 氯化亚砜 作用下， 反应 4.0h， 生成 4-(2-(dimethylamino)ethoxy)benzoyl chloride
  参考文献：
  名称：

  [EN] INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY
  [FR] INHIBITEURS DE LA VOIE WNT/BÊTA-CATÉNINE

  摘要：

  本披露涉及能够调节WNT/Beta-Catenin通路的化合物。此外，该披露还涉及治疗结直肠癌和其他WNT/Beta-Catenin介导的癌症的方法。

  公开号：

  WO2019152536A1
• 作为产物：
  描述：

  methyl 4-(2-(dimethylamino)ethoxy)benzoate 在 sodium hydroxide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 以80%的产率得到4-(2-二甲基氨基乙氧基)苯甲酸盐酸盐
  参考文献：
  名称：

  [EN] INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY
  [FR] INHIBITEURS DE LA VOIE WNT/BÊTA-CATÉNINE

  摘要：

  本披露涉及能够调节WNT/Beta-Catenin通路的化合物。此外，该披露还涉及治疗结直肠癌和其他WNT/Beta-Catenin介导的癌症的方法。

  公开号：

  WO2019152536A1

文献信息

• Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
  申请人：Eli Lilly and Company

  公开号：US04358593A1

  公开（公告）日：1982-11-09

  The use of particularly advantageous protecting groups for the hydroxy groups of 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophenes provides a high-yielding process for the preparation of such compounds having a 4-(2-aminoethoxy)benzoyl 3-group.

  特别有利的保护基团用于对6-羟基-2-(4-羟基苯基)苯并[b]噻吩的羟基，提供了一种高产率的制备具有4-(2-氨基乙氧基)苯甲酰基3基团的化合物的方法。
• Synthesis of acylated benzothiophenes
  申请人：Eli Lilly and Company

  公开号：US04380635A1

  公开（公告）日：1983-04-19

  A group of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-aminoethoxy)benzoyl]benzo[b]thiophen es are prepared by acylation of a methyl-protected starting compound followed by demethylation in a single reaction mixture.

  一组6-羟基-2-(4-羟基苯基)-3-[4-(2-氨基乙氧基)苯甲酰基]苯并噻吩通过对一种甲基保护的起始化合物进行酰化，然后在单一反应混合物中进行去甲基化制备。
• Pyrazolopyrimidine compound and a process for preparing the same
  申请人：Takamuro Iwao

  公开号：US20060135525A1

  公开（公告）日：2006-06-22

  The present invention provides a novel pyrazolopyrimidine compound of the formula [I]: wherein R′ is (A) a substituted aryl group, (B) an optionally substituted nitrogen-containing aliphatic heteromonocyclic group, (C) a substituted cyclo-lower alkyl group, (D) an optionally substituted amino group, or (E) a substituted heteroaryl group, R 2 is (a) an optionally substituted heteroaryl group or (b) an optionally substituted aryl group, Y is a single bond, a lower alkylene group or a lower alkenylene group, Z is a group of the formula: —CO—, —CH2-, S02- or a group of the formula [II]: Q is a lower alkylene group, and q is an integer of 0 or 1 or a pharmaceutically acceptable sait thereof, which has a small conductance potassium channel (SK channel) blocking activity and is useful as a medicament and a process for preparing the same.

  本发明提供了一种新型的吡唑嘧啶化合物，其化学式为[I]：其中R′为（A）取代芳基，（B）可选取代的含氮脂肪杂环基，（C）取代的环低烷基，（D）可选取代的氨基或（E）取代的杂环芳基；R2为（a）可选取代的杂环芳基或（b）可选取代的芳基；Y为单键，低碳基烷基或低碳基烯基；Z为式[II]的基团：其中Q为低碳基烷基，q为0或1的整数，或其药学上可接受的盐。该化合物具有小电导钾通道（SK通道）阻滞活性，并可作为药物使用，以及其制备方法。
• 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
  申请人：Novo Nordisk A/S

  公开号：US06177443B1

  公开（公告）日：2001-01-23

  The present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a compound of formula I wherein A together with the double bond of formula I is benzene or thiophene; R1 is optionally substituted C1-6 alkyl or optionally substituted aryl; R2 is optionally substituted C1-6-alkyl, optionally substituted aralkyl, or —COR3, wherein R3 is optionally substituted C1-6-alkyl, optionally substituted aralkyl, or optionally substituted aryl; R4 and R5 independently are hydrogen, halogen, perhalomethyl, optionally substituted C1-6-alkyl, hydroxy, optionally substituted C1-6-alkoxy, nitro, cyano, amino, optionally substituted mono- or optionally substituted di-C1-6-alkylamino, acylamino, C1-6-alkoxycarbonyl, carboxy or carbamoyl; n is 0, and m is 1, and methods of treating or preventing a disease of the endocrinologic system.

  本发明涉及药物组合物，包括药用可接受载体或稀释剂和式I化合物，其中A与式I的双键一起是苯或噻吩；R1是可选取代的C1-6烷基或可选取代的芳基；R2是可选取代的C1-6烷基，可选取代的芳基烷基，或-COR3，其中R3是可选取代的C1-6烷基，可选取代的芳基烷基，或可选取代的芳基；R4和R5独立地是氢，卤素，全卤甲基，可选取代的C1-6烷基，羟基，可选取代的C1-6烷氧基，硝基，氰基，氨基，可选取代的单-或可选取代的双C1-6烷基氨基，酰胺基，C1-6烷氧羰基，羧基或氨基甲酰；n为0，m为1，以及治疗或预防内分泌系统疾病的方法。
• 1-[4-(2-Dimethylaminoethoxy)phenylcarbonyl]-3,5-Bis(3,4,5-Trimethoxybenzylidene)- 4-Piperidone Hydrochloride and Related Compounds: Potent Cytotoxins Demonstrate Greater Toxicity to Neoplasms than Non- Malignant Cells
  作者：Praveen K. Roayapalley、Jonathan R. Dimmock、Hiroshi Sakagami、Noriyki Okudaira、Rajendra K. Sharma、Umashankar Das

  DOI：10.2174/1573406418666220322154110

  日期：2022.11

  The incidence of cancer has been increasing worldwide. Unfortunately, the drugs used in cancer chemotherapy are toxic to both neoplasms and normal tissues, while many available medications have low potencies. Conjugated α,β-unsaturated ketones differ structurally from contemporary anticancer medications, and some of which have

  To design and synthesize highly potent cytotoxins with far greater toxicity to neoplasms than to non-malignant cells.

  A series of N-acyl-3,5-bis(benzylidene)-4-piperidone hydrochlorides 4a-n were prepared and evaluated against Ca9-22, HSC-2, HSC-3, and HSC-4 squamous cell carcinomas as well as aginst HGF, HPLF, and HPC non-malignant cells. QSAR and western blot analyses were performed.

  The majority of compounds display submicromolar CC50 values towards the neoplasms; the figures for some of the compounds are below 10-7 M. In general, 4a-n have much lower CC50 values than those of melphalan, 5-fluorouracil, and methotrexate, while some compounds are equitoxic with doxorubicin. The compounds are far less toxic to the non-malignant cells, giving rise to substantial selectivity index (SI) figures. A QSAR study revealed that both potency and the SI data were controlled to a large extent by the electronic properties of the substituents in the arylidene aryl rings. Two representative compounds 4f and 4g caused apoptosis in HSC-2 cells.

  The compounds in series 4 are potent cytotoxins displaying tumor-selective toxicity. In particular, 4g with an average CC50 value of 0.04 µM towards four malignant cell lines and a selectivity index of 46.3 is clearly a lead molecule that should be further evaluated.

  背景：癌症发病率正在全球范围内增加。不幸的是，用于癌症化疗的药物对肿瘤和正常组织都有毒性，而许多可用药物的效力较低。共轭α，β-不饱和酮在结构上与现代抗癌药物不同，其中一些具有... 目标：设计和合成高效的细胞毒素，对肿瘤细胞的毒性远高于非恶性细胞。 方法：制备了一系列N-酰基-3,5-双(苄亚甲基)-4-哌啶酮盐酸盐4a-n，并对Ca9-22、HSC-2、HSC-3和HSC-4鳞状细胞癌以及HGF、HPLF和HPC非恶性细胞进行了评估。进行了QSAR和Western blot分析。 结果：大多数化合物在肿瘤细胞上显示亚微摩尔水平的CC50值；其中一些化合物的数值低于10-7 M。总体而言，4a-n的CC50值远低于甲氧氨基甲烷、5-氟尿嘧啶和甲氨蝶呤，而一些化合物与多柔比星的毒性相当。这些化合物对非恶性细胞的毒性远低于肿瘤细胞，产生了相当大的选择性指数（SI）值。QSAR研究表明，芳基亚甲基环上取代基的电子性质在很大程度上控制了效力和SI数据。两个代表性化合物4f和4g在HSC-2细胞中引起了凋亡。 结论：系列4中的化合物是具有肿瘤选择性毒性的有效细胞毒素。特别是4g，其对四种恶性细胞系的平均CC50值为0.04 µM，选择性指数为46.3，显然是一个应该进一步评估的领头化合物。